<DOC>
	<DOCNO>NCT02978417</DOCNO>
	<brief_summary>In preparation large-scale randomize control trial ( RCT ) Vivitrol® effectiveness drug court , investigator propose feasibility study Wake County , North Carolina drug court , estimate 50 % client opioid dependent . Aim 1 : Pilot RCT . Pilot-test delivery Vivitrol® treatment 10-20 interested eligible client Wake County Drug Court .</brief_summary>
	<brief_title>Feasibility Study Extended-release Naltrexone ( Vivitrol ) Drug Court Settings</brief_title>
	<detailed_description>Aim 1 . Pilot RCT . The pilot delivery Vivitrol® Wake County Drug Court carry 20-40 eligible drug court client treatment Fellowship Health Resources , Inc. ( FHR ) , community behavioral health treatment agency contract treatment provider Wake County Drug Court . Participants randomize equal number receive Vivitrol® plus treatment usual ( TAU ) TAU . TAU drug court client receive service FHR include psychosocial treatment individual group therapy , sometimes also oral naltrexone client medically eligible interested take medication , cost cover agency uninsured client . ( FHR currently administer Vivitrol® small number interested agency client health insurance cover medication ; vast majority drug court client uninsured real access extended-release formulation due high cost . Any drug court client insure , thereby access Vivitrol® , eligible study . ) Vivitrol® FDA-approved extended-release injectable form naltrexone . Naltrexone also available oral , extended release , form . Naltrexone opioid antagonist `` block '' opioid receptor brain stop pleasurable feeling associate take opioids . Potentially eligible subject drug court-referred FHR client willing eligible take Vivitrol® , willing randomly assign Vivitrol® TAU . Potential subject already treatment oral naltrexone FHR would eligible enter study willing switch injectable Vivitrol® randomly assign . Study subject randomize Vivitrol® would receive once-monthly injection Vivitrol® 12 month , less decide stop receiving Vivitrol® drop study . Those randomized TAU would continue treatment , could include ( 1 ) stay oral naltrexone already , ( 2 ) consider start oral naltrexone , interested , ( 3 ) continue psychosocial treatment . The Vivitrol® administer study medical personnel FHR . Randomization Vivitrol® arm would add urine pregnancy test FHR 's exist Vivitrol® medical evaluation protocol consent process , currently screen pregnancy without require urine test . A urine pregnancy test administer per month female study participant child-bearing age Vivitrol® group . All drug court client , include study participant study group , urine drug test least per week part program participation . In addition participate Vivitrol® psychosocial treatment , pilot RCT participant provide consent FHR drug court share information study team demographic clinical characteristic , treatment participation ( e.g. , outpatient group therapy ) , court-related event ( e.g. , type conviction lead drug court participation , miss drug court appointment , sanction program violation , result drug screen ) . Participants also provide two face-to-face interview baseline 6 month baseline , interest experience Vivitrol® and/or medication-assisted treatment ( MAT ) , treatment preference , level functioning , quality life , engagement employment education . Outcome measure include treatment participation , compliance drug court condition , arrest incarceration , treatment satisfaction , self-reported subjective measure function quality life . If participant chooses participate study time , affect his/her relationship court , FHR , right health care , participation study interview data collection . Site staff follow participant purpose collect research safety information . Investigators discontinue Vivitrol® oral naltrexone circumstance : adverse reaction medication ; change medical status make unsafe participant continue receive medication , include pregnancy ; participant become ill study . Participants discontinue Vivitrol® oral naltrexone reason may continue participate interview study .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Client Wake County Drug Treatment Court Interested medicationassisted treatment opioid dependence 1865 year old understands speak English understands study participation fully voluntary , effect court stand willing able give write informed consent opioid use disorder ( DSM5 diagnosis moderate severe opioid use disorder ) ( female ) intend become pregnant breastfeeding study period willing adhere contraception requirement study period willing adhere study treatment protocol Has least 710 day without opioid use begin extendedrelease injectable naltrexone give detoxification opioids initiate resume extendedrelease injectable naltrexone necessary prevent withdrawal . Exclusion Criteria* : Is pregnant ( i.e. , positive pregnancy test ) , plan become pregnant , breastfeed study Has positive urine drug test opioids , buprenorphine methadone begin treatment Vivitrol® injection Has use opioid drug within 10 day prior treatment Has condition , disease state , previous medical history , observed abnormality ( include physical examination , laboratory evaluation [ e.g. , kidney liver function test result ] , urinalysis find ) screening , opinion investigator , would preclude safe participation study affect ability subject adhere protocol visit schedule , fulfill visit requirement , would interfere study assessment , include , limited , follow : Uncontrolled hypertension , uncontrolled diabetes , renal disease/impairment , stroke , seizures neurological disorder , cardiovascular ( eg , endocarditis ) , neoplastic disease Chronic pain condition require ongoing opioid analgesia Aspartate aminotransferase alanine aminotransferase value ≥3 time upper limit normal Any contraindicate medical condition per approve label naltrexone Has DSM5 Diagnosis within past 12 month psychiatric condition disorder , investigator 's opinion , could interfere participation study Is currently physiologically dependent psychoactive substance ( except caffeine , tobacco ) require medical intervention detoxification Has history hypersensitivity adverse reaction naltrexone , naloxone Has significant suicidal ideation behavior within past year , assess Global Appraisal Individual Needs Short Screener ( GAINSS ) Substance Abuse Mental Health Services Administration 's Government Performance Results Act ( GPRA ) Client Outcome Instrument . Under electronic house arrest ( court client less restrictive electronic monitoring eligible ) . Note exclusion criterion : If , join study , subject positive drug test , become pregnant , acquire another exclusion condition would prevent him/her join study , may remain study permit receive Vivitrol® . Study staff continue gather interview data administrative data enrol , willing subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Medication-assisted treatment</keyword>
	<keyword>Drug Court</keyword>
	<keyword>Pilot study</keyword>
	<keyword>Opioid dependence</keyword>
	<keyword>Criminal justice</keyword>
</DOC>